The Translational Research Working Group Developmental Pathway for anticancer agents (drugs or biologics)

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5685-5691

  Schilsky, Richard L ^a,b   Gordon, Gary ^a,c   Gilmer, Tona M ^a,d   Courtneidge, Sara A ^a,e   Matrisian, Lynn M ^a,f   Grad, Oren ^a,g   Nelson, William G ^a,h,i  

^a Translational Research Working Group

^b UNIVERSITY OF CHICAGO   (United States)

^c ABBOTT LABORATORIES   (United States)

^d GLAXOSMITHKLINE   (United States)

^e BURNHAM INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g Science and Technology Policy Institute   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; ERLOTINIB; GEFITINIB; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; CANCER VACCINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RESEARCH; CLINICAL TRIAL; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; ARTICLE; COMPUTER PROGRAM; DRUG DELIVERY SYSTEM; DRUG DESIGN; HEALTH CARE ORGANIZATION; NEOPLASM; PROGRAM DEVELOPMENT; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PROGRAM DEVELOPMENT; SOFTWARE DESIGN; UNITED STATES;

EID: 53249111807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1265     Document Type: Review

References (39)

1. Hawk ET, Matrisian LM, Nelson WG, et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 2008;14:5664-71.
2. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960;132: 1497-7.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
5. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990;87:6649-53.
6. [Erratum, Proc Natl Acad Sci U S A 1990;87:9072.]
7. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3.
8. LugoTG, Pendergast AM, MullerAJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science1990;247:1079-82.
9. Druker BJ. Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
10. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
11. [Erratum, N EnglJ Med 2002;346:1923.]
12. Shepard FA, Periera JR, CiuleanuT, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32.
13. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005;23:5856-8.
14. Fukuoka M. Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL1 trial). J Clin Oncol 2003;21:2237-46.
15. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
16. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
17. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and nonsmall cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
20. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
21. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
22. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
23. Pao W. Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med doi: 10.1371/Journal. pmed. 0020017.
24. Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature 2006;441:451-6.
25. Srivastava S, Gray JW, Reid BJ, et al. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 2008;14:5672-7.
26. Schwartz AL, Ciechanover A. The ubiquitin-proteasomepathway and pathogenesis of human diseases. Annu Rev Med 1999;50:57-74.
27. Palombella VJ, Rando OJ, Goldberg AL, ManiatisT. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994;78:773-85.
28. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science (Washington DC) 1996;274:782-84.
29. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
30. Wang C-Y, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
31. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-κB in streptococcal cell wallinduced polyarthritis. Proc Natl Acad Sci U S A 1998; 95:15671-6.
32. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
33. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
34. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000:46:673-83.
35. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500.
36. Hideshima T Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2004;61: 3071-6.
37. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
38. Broff PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10:3954-64.
39. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.